Diagnostic company focused on improving organ transplant outcomes through molecular diagnostics.
CareDx, Inc. is a pioneering company dedicated to discovering, developing, and distributing innovative diagnostic solutions tailored for transplant patients and their caregivers worldwide. Established in 1998 and headquartered in South San Francisco, California, CareDx focuses on advancing technologies that enhance patient outcomes post-transplantation.
The company's flagship products include AlloSure Kidney and AlloSure Heart, which utilize donor-derived cell-free DNA (dd-cfDNA) to provide precise surveillance solutions for kidney and heart transplant recipients, respectively. Additionally, CareDx offers AlloMap Heart, a gene expression test designed for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution tailored for lung transplant patients.
CareDx extends its portfolio with TruSight HLA, a next-generation sequencing (NGS) based high-resolution typing solution, and Olerup SSP, which employs sequence-specific primer technology to type human leukocyte antigen (HLA) alleles. The company's comprehensive offerings also include Ottr, a transplant patient management software, and AlloSeq Tx, a high-resolution HLA typing solution.
In collaboration with partners like Illumina, Inc., CareDx leverages cutting-edge NGS technologies for the development and distribution of advanced diagnostic tools. The company also collaborates with Cibiltech SAS to commercialize iBox, a software platform for predictive analysis of kidney allograft loss post-transplantation. CareDx continues to innovate and expand its reach in the healthcare industry, delivering critical solutions that improve the monitoring, management, and quality of life for transplant recipients globally.